FISCHER JOST
Known title: DirectorCIK: 0001366841
FISCHER JOST's purchase track record
FISCHER JOST has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 5/19/2025 | AEON | $85K | +48.3% | +70.9% | +11.9% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| AEON | ▲ Buy | Grant | 222,684 | $0 | 6/17/2026 | View on chart |
| AEON | ▲ Buy | Open Market | 60,000 | $29K | 5/21/2025 | View on chart |
| AEON | ▲ Buy | Open Market | 60,000 | $30K | 5/20/2025 | View on chart |
| AEON | ▲ Buy | Open Market | 50,000 | $25K | 5/19/2025 | View on chart |
| AEON | ▲ Buy | Grant | 36,021 | $0 | 8/31/2024 | View on chart |
| AEON | ▲ Buy | Grant | 2,353 | — | 7/21/2023 | View on chart |
| AEON | ▲ Buy | Grant | 13,274 | — | 7/21/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
AEON Biopharma Shares FDA Feedback on ABP-450 Biosimilar Plan
AEON Biopharma received feedback from the FDA following a Type 2b meeting, which helps clarify the development path for its ABP-450 biosimilar candidate. This regulatory update provides specific guidance on the next steps for the company's pipeline. The stock recently appeared on lists of active healthcare names, reflecting market interest in this regulatory progress.
AEON Biopharma Shares FDA Feedback on ABP-450 Biosimilar Plan. AEON Biopharma received feedback from the FDA following a Type 2b meeting, which helps clarify the development path for its ABP-450 biosimilar candidate. This regulatory update provides specific guidance on the next steps for the company's pipeline. The stock recently appeared on lists of active healthcare names, reflecting market interest in this regulatory progress.